NextBio will use the funds to develop its vertebrate and plant information platform for cross-species research.
The merger will combine Eureka's bioinformatics capabilities with Nanobac's drug discovery program focused on inhibiting, destroying, or neutralizing calcifying nanoparticles.
Some of NIH's and NHGRI's challenge grants will give priorities to ethical issues that confront genomics, pharmacogenomics, and biomedicine.
Verdezyne will optimize selected genes that encode industrial enzymes for Novozymes.
Complete Genomics has been forced to cut staff salaries and take other cost-saving steps as its Series D financing round has been delayed in closing.
Developing high-throughput technologies, personalized medicine, and data handling tools are the focus of the NIH/NHGRI challenge grants.
The companies have partnered to integrate the Geneus software for use with ABI's next-generation sequencing system.
Nearly $14 million next year will support centers to study malaria and develop gene-based diagnostics.
The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.
A trio of researchers involved in the Cancer Genome Project at the Wellcome Trust Sanger Institute published a review article today outlining what's known about the cancer genome, remaining questions, and the future of the field.
James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.
The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.
Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.
In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.